| Previous close | 0.8000 |
| Open | 0.6500 |
| Bid | 0.4000 |
| Ask | 0.7500 |
| Strike | 1.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.6500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 377 |
Simply Wall St.Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the GlycoMimetics, Inc. ( NASDAQ:GLYC ) Senior VP...
Business WireGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md., June 04, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML.
Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
ROCKVILLE, Md., May 29, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company’s pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
